Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD0901 in Advanced Solid Tumours Expressing Claudin 18.2 (CLARITY-PanTumour01)
NCT06219941Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2023
- Primary completion
- Nov 2026
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 14
01
Overview
Phase 2, randomised, open-label trial of sonesitatug vedotin in gastric cancer (GC), gastroesophageal junction cancer, biliary tract cancer (BTC) and 1 more (3 arms), sponsored by AstraZeneca. Primary endpoints: Incidence of adverse events and Objective Response Rate. Started Dec 2023; status: recruiting.
02
Drugs
sonesitatug vedotin
03
Conditions
gastric cancer (GC)gastroesophageal junction cancerbiliary tract cancer (BTC)pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06219941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06219941.